Related coverage linked through entity extraction aliases.
Aug 20, 2026
XRP price flashed a gravestone doji after a $1.35-$1.65 rally, signaling potential reversal. Analysts target $0.80-$0.91 based on the 200-week EMA loss and Gaussian Channel, while key resistance sits at $2.10-$2.14.
Jul 28, 2026
GLP-1 receptor agonists are linked to a higher risk of smell and taste disturbances, while poison control calls involving semaglutide have soared since 2021. The drugs produce significant weight loss and are reshaping U.S. food demand, with roughly one in eight adults now taking them.
May 26, 2026
Iovance's Amtagvi achieved a 44% confirmed objective response rate and 73% disease control in an advanced melanoma study. Goldman Sachs raised its price target to $2, maintaining a Sell rating.
May 14, 2026
Vanguard and Goldman Sachs forecasts pointed to stronger long-term returns for international stocks than for U.S. equities. The articles highlighted broad international, European and emerging-market ETFs with low expense ratios and large exposure to non-U.S. markets.
Feb 26, 2026
Crinetics Pharmaceuticals reported over $5 million in preliminary net product revenue for PALSONIFY in Q4 2025, while Phase 2 data for its congenital adrenal hyperplasia treatment showed promising results that analysts say have derisked the Phase 3 study design.
Feb 25, 2026
Medtronic's diabetes unit MiniMed is seeking up to $7.86 billion valuation in its U.S. IPO while cutting 81 jobs at its Northridge facility ahead of the planned separation into a standalone publicly traded company.
